Skip to content
Research Article Open access CC BY 3.0

Lipoprotein Lipase Expression, Serum Triacylglycerol and Tissue Lipid Deposition in Rats Fed on Switching Type of Diet and Treated with Glycyrrhizic Acid

Hui Ping Yaw, So Ha Ton, Shing Wei Ng, Khalid Abdul Kadir

European Journal of Medicinal Plants · pp. 145–157 · Published 3 Dec 2013

10.9734/EJMP/2014/6700

Abstract

Aims: To determine the anti-hyperglycaemic and anti-hyperlipidaemic effects of glycyrrhizic acid (GA), the root extract of Glycyrrhiza glabra in rats with switching type of diet i.e. between normal diet (ND) and high-fat diet (HFD). Study Design:  In vivo study. Place and Duration of Study: School of Science, Monash University Sunway Campus between January 2010 and October 2010. Methodology: Sixteen Sparague-Dawley rats were divided into two groups having eight animals each i.e. group A- ND+GA→ HFD+GA; group B- ND+GA→HFD+no GA. Rats were fed with the corresponding diet and GA (100 mg/kg) for 28 days. The blood glucose, insulin and triacylglycerol levels, lipoprotein lipase expression in the liver, kidney, heart, abdominal muscle (AM), quadriceps femoris (QF), subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) and tissue lipid deposition were measured. Results: No significant difference in blood glucose levels between groups. GA significantly lowered (P=.05) triacylglycerol in rats fed on a ND with GA and later switched to a HFD without GA (group B) compared to rats fed on a ND with GA and later switched to a HFD with continuous GA supplementation (group A). For LPL expression, group B had significant lower (P=.05) LPL expression in the liver, AM, kidney and heart than group A. Group A had significantly smaller (P=.05) size of VAT than group B. Conclusion: These findings may indicate the role of GA in lowering blood glucose and triacylglycerol in subjects who had a switch from a ND with GA to a HFD without GA but not in those who had a switch from a ND with GA to a HFD with continuous GA supplementation.  

Glycyrrhizic acid lipoprotein lipase tissue lipid deposition triacylglycerol high-fat diet

References (28)

  1. 1 Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR [DOI]
  2. 2 Adipose Tissue as an Endocrine Organ [DOI]
  3. 3 Abdominal obesity and metabolic syndrome [DOI]
  4. 4 Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction [DOI]
  5. 5 Lipoprotein lipase: structure, function, regulation, and role in disease [DOI]
  6. 6 Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin [DOI]
  7. 7 Liver disease and diabetes mellitus.
  8. 8 Fatty liver and lipotoxicity [DOI]
  9. 9 Regulation of Lipoprotein Lipase by the Oxysterol Receptors, LXRα and LXRβ [DOI]
  10. 10 Prevalence of metabolic syndrome and its risk factors in adult Malaysians: Results of a nationwide survey [DOI]
  11. 11 Molecular pathobiology of the human lipoprotein lipase gene [DOI]
  12. 12 Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution [DOI]
  13. 13 Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats [DOI]
  14. 14 Cardiac-specific Knock-out of Lipoprotein Lipase Alters Plasma Lipoprotein Triglyceride Metabolism and Cardiac Gene Expression [DOI]
  15. 15 Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance [DOI]
  16. 16 Fibre types in human abdominal muscles [DOI]
  17. 17 Lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally-administered glycyrrhizic acid-treated rats [DOI]
  18. 18 Biological specificity of visceral adipose tissue and therapeutic intervention [DOI]
  19. 19 Effects of Glycyrrhizic Acid on Peroxisome Proliferator-Activated Receptor Gamma (PPAR γ ), Lipoprotein Lipase (LPL), Serum Lipid and HOMA-IR in Rats [DOI]
  20. 20 Adipocyte apoptosis in the regulation of body fat mass by leptin [DOI]
  21. 21 Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects [DOI]
  22. 22 Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γ [DOI]
  23. 23 Agonists of the Peroxisome Proliferator–Activated Receptor Alpha Induce a Fiber-Type–Selective Transcriptional Response in Rat Skeletal Muscle [DOI]
  24. 24 Glycyrrhizic Acid Improves Lipid and Glucose Metabolism in High-Sucrose-Fed Rats [DOI]
  25. 25 Structure and polymorphic map of human lipoprotein lipase gene [DOI]
  26. 26 Morphological changes of the adipose cell plasma membrane during lipolysis. [DOI]
  27. 27 Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver [DOI]
  28. 28 Corrigendum to “Prevalence of metabolic syndrome and its risk factors in adult Malaysians: Results of a nationwide survey” [Diabetes Res. Clin. Pract. 91 (2011) 239–245] [DOI]

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

16

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.